secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001753926-25-000842
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP
--------------------------------------------------------------------------------

- Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
- OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).
- No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.
- Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/0001753926-25-000842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/g084819_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer